3 Earnings Reports That Caught My Attention Last Week

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

As fourth-quarter earnings reports are nearing an end, and with three-quarters of the year already in the books, I can't help but point out that the majority of reports up until now have been better than expected. With so many companies reporting during the weeks that comprise earnings season, it's easy for some earnings reports to fall through the cracks.

Each week this year, I've taken a look at three companies that could be worth further research after either beating or missing their profit expectations. Today, we'll take a gander at three more companies that reported earnings last week. They may have slid under your radar, but they deserve a look.


Consensus EPS

Reported EPS


Rite Aid (NYSE: RAD  )




FedEx (NYSE: FDX  )




Navistar (NYSE: NAV  )




Source: Yahoo! Finance.

Rite Aid
Warning! Objects in the mirror may appear a lot closer than they actually are! Yes, Rite Aid did turn in its first quarterly profit in five years, but the drugstore chain is a long way from escaping the quicksand.

Rite Aid's most recent quarter received a nice boost from the spat between Express Scripts (NASDAQ: ESRX  ) and Walgreen (NASDAQ: WBA  ) earlier this year, which only ended in mid-September. Between CVS Caremark (NYSE: CVS  ) and Rite Aid continuing to fill Express Scripts prescriptions and a newly introduced loyalty rewards program, Rite Aid cleaned up its aisles nicely. But, as I alluded to above, this looks like a temporary fix for a still struggling franchise.

Walgreen and Express Scripts are working together once again, leading me to believe that Rite Aid is going to struggle to retain the customers it gained from Walgreen. I think Rite Aid's fiscal 2013 same-store sales guidance of minus 0.3% to minus 0.9% speaks volumes about how abnormal this most recent quarter was! Rite Aid is still working with $5.8 billion in long-term debt and the introduction of generic medication is crippling its pharmacy margins. Make no mistake about it, Rite Aid is still in just as much trouble now as it was two weeks ago prior to this report.

The headline number from FedEx might be a $0.02 earnings shortfall, but to me this was an earnings beat in every other sense.

For the quarter, FedEx recorded an $0.11 hit due to Superstorm Sandy -- a relatively rare event. Beyond the storm, FedEx noted that revenue for the quarter rose 5% to $11.1 billion despite the fact that its customers have been pushing shipments out longer and have been shipping by sea in some cases, and that the company has dealt with very weak demand in Europe.

One key aspect to FedEx being able to maintain its full-year forecast has to do with its ability to use its brand power to raise its prices. Twice, recently, FedEx has boosted its prices and the company appears on track for another record Christmas quarter according to management. Another factor that will soon be working in FedEx's favor will be fiscal cliff clarity. Once consumers and businesses know the resolution to their tax situations, I believe you'll see enterprise orders and shipping demand resume quickly. Outside of one-time events, FedEx's results seem right on par to me!

There are quarterly losses, and then there's the monster loss that the restructuring Navistar leveled on investors last week.

Navistar, a manufacturer of diesel engines, has dealt with a myriad of issues this year, including diesel engine redesigns as well as weakened domestic and overseas demand. Its latest setback was an obscenely large $2 billion tax expense that, when added in with restructuring costs and a 24% decline in revenue, resulted in a $2.77 billion loss! Keep in mind that Navistar's market value is only $1.6 billion, so you'd be correct in assuming that activist shareholder Carl Icahn wasn't pleased and is still trying to effect change on the board.

Ironically enough, I actually found these results to be somewhat encouraging because it shows that Navistar may be turning the corner. For one thing, Navistar's cost-cutting plan is ahead of schedule. Clearly I'd rather the company be growing top-line earnings than backing its way into a profit, but baby steps are never a bad thing after a loss this big. Also, the simple need for more fuel-efficient engines as trucking companies look to become more fuel-efficient and lower their fuel costs should make Navistar an intriguing rebound candidate. This quarter may have been a wash, but keep your eyes on Navistar moving forward.

Foolish roundup
Sometimes an earnings beat or miss isn't as cut-and-dried as it appears. I've given my two cents on what's next for each of these companies -- now it's your turn to sound off. Share your thoughts in the comments section below and consider adding these stocks to your free and personalized Watchlist.

Express Scripts shares took a massive dive after a recent earnings report. Has the company's long-term outlook really changed, or is this a classic example of Wall Street being blinded by its short-term lens? In this brand-new premium report on Express Scripts, Stock Advisor analyst Jim Mueller dives deep into the company's prospects. Here's a hint: There's plenty of room for growth. You'll understand why, along with an outline of the key must-watch areas of the company, if you claim a copy by clicking here now.

Read/Post Comments (2) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On December 24, 2012, at 2:00 PM, safesailor wrote:

    The author says:" and the introduction of generic medication is crippling its pharmacy margins. Make no mistake about it, Rite Aid is still in just as much trouble now as it was two weeks ago prior to this report."

    In all the other articles the increase in generic usage INCREASES prescription margins. It does decrease total sales but it increases profit margins. Also the script count totals have been trending up for some time and the Christmas quarter is usually the most profitable of the 4. I do, however, agree that Rite Aid is not out of the woods yet, but I think they are in better shape than they were 3 months ago.

  • Report this Comment On December 25, 2012, at 8:40 AM, figglebird wrote:

    Just to reiterate, huh???

    Generics INCREASE MARGINS - DECREASE REVS. They help the bottom line and hurt the top.

    Author should correct this as it's just plain wrong, misleading, and puts into question credibility.

    Also, w respect to WAG regaining their lost customer base - what is author basing this on? A hunch? Is there some plan in place? Not sure people have any loyalty when it comes to corporate pharmacies.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2168019, ~/Articles/ArticleHandler.aspx, 10/22/2016 6:04:26 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 20 hours ago Sponsored by:
DOW 18,145.71 -16.64 -0.09%
S&P 500 2,141.16 -0.18 -0.01%
NASD 5,257.40 15.57 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 4:02 PM
FDX $170.20 Up +0.50 +0.29%
FedEx CAPS Rating: ****
NAV $23.03 Up +0.03 +0.13%
Navistar Internati… CAPS Rating: **
RAD $7.04 Down -0.07 -0.98%
Rite Aid CAPS Rating: ****
CVS $87.41 Up +0.11 +0.13%
CVS Health CAPS Rating: ****
ESRX $69.61 Down -1.43 -2.01%
Express Scripts CAPS Rating: *****
WBA $81.57 Up +0.55 +0.68%
Walgreens Boots Al… CAPS Rating: ****